Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIM-004 (afamelanotide)
- Development stage
- Unknown
- Lead developer
- Vimela Therapeutics
- Modality
- Peptides
- Administration
- Topical
01
Overview
VIM-004 is a topical gel formulation of afamelanotide, a synthetic peptide analogue of alpha-melanocyte stimulating hormone (α-MSH). Developed by Vimela Therapeutics, it is designed to treat vitiligo by targeting the melanocortin 1 receptor (MC1R) to stimulate melanocyte activity and promote skin repigmentation. Unlike systemic formulations of afamelanotide (such as the subcutaneous implant Scenesse), VIM-004 is applied topically to localized areas of depigmentation. It is currently being evaluated in Phase Ib/IIa clinical trials in combination with narrowband ultraviolet B (NB-UVB) phototherapy to evaluate its safety and preliminary efficacy in enhancing repigmentation in adults with vitiligo, particularly in refractory areas. The drug represents an orthogonal approach to existing immunomodulatory therapies by directly stimulating the pigment-producing cells.
- Other names
- [Nle4, D-Phe7]-alpha-MSHMelanotan I
02
Targets
CREB (Cyclic AMP response element-binding protein)MC1R (Melanocortin Type 1 Receptor)MC3R (Melanocortin Receptor Type 3)MC4R (Melanocortin 4 receptor)MC5R (Melanocortin 5 Receptor)MITF (Melanocyte inducing transcription factor)TYRP1 (Tyrosinase-related protein 1)TYRP2 (Tyrosinase-related Protein 2)AC (Adenylyl cyclase family)PKA (Cyclic amp-dependent protein kinase)TYR (Tyrosinase)
Beyond the preview
Go deeper on VIM-004 (afamelanotide).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIM-004 (afamelanotide).